120 related articles for article (PubMed ID: 35526525)
21. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
22. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
23. Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Indini A; Tondini CA; Mandalà M
Future Oncol; 2019 Mar; 15(9):967-977. PubMed ID: 30638071
[TBL] [Abstract][Full Text] [Related]
24. Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel.
Ramesh J; Thilakan RC; Gopalakrishnan RM; Vijayapoopathi S; Dorschel A; Venugopal B
Genes (Basel); 2022 Jun; 13(7):. PubMed ID: 35885925
[TBL] [Abstract][Full Text] [Related]
25. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Lieu CH; Hidalgo M; Berlin JD; Ko AH; Cervantes A; LoRusso P; Gerber DE; Eder JP; Eckhardt SG; Kapp AV; Tsuhako A; McCall B; Pirzkall A; Uyei A; Tabernero J
Oncologist; 2017 Sep; 22(9):1024-e89. PubMed ID: 28592615
[TBL] [Abstract][Full Text] [Related]
26. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
27. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells.
Lee KH; Yim EK; Kim CJ; Namkoong SE; Um SJ; Park JS
Gynecol Oncol; 2005 Jul; 98(1):45-53. PubMed ID: 15907983
[TBL] [Abstract][Full Text] [Related]
28. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
Sriraman SK; Geraldo V; Luther E; Degterev A; Torchilin V
J Control Release; 2015 Dec; 220(Pt A):160-168. PubMed ID: 26497930
[TBL] [Abstract][Full Text] [Related]
30. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
31. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells.
He L; Yang H; Zhou S; Zhu H; Mao H; Ma Z; Wu T; Kumar AK; Kathera C; Janardhan A; Pan F; Hu Z; Yang Y; Luo L; Guo Z
DNA Repair (Amst); 2018 Mar; 63():1-9. PubMed ID: 29358095
[TBL] [Abstract][Full Text] [Related]
33. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
34. Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro.
Yu J; Zhao Y; Liu C; Hu B; Zhao M; Ma Y; Jiang J
Clin Transl Oncol; 2020 Jan; 22(1):60-69. PubMed ID: 31093891
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL; Durham BH; Ulaner GA; Drill E; Buthorn J; Ki M; Bitner L; Cho H; Young RJ; Francis JH; Rampal R; Lacouture M; Brody LA; Ozkaya N; Dogan A; Rosen N; Iasonos A; Abdel-Wahab O; Hyman DM
Nature; 2019 Mar; 567(7749):521-524. PubMed ID: 30867592
[TBL] [Abstract][Full Text] [Related]
36. Marine Sulfated Polysaccharide PMGS Synergizes with Paclitaxel in Inhibiting Cervical Cancer In Vitro.
Xia X; Wang Y; Shao Y; Xu J; Liang B; Liu W; Zeng J; Li C; Guan H; Wang S; Xing D
Mar Drugs; 2023 Apr; 21(5):. PubMed ID: 37233453
[TBL] [Abstract][Full Text] [Related]
37. Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
Gauci ML; Laly P; Leonard-Louis S; Behin A; Gottlieb J; Madelaine-Chambrin I; Baroudjian B; Da-Meda L; Mourah S; Battistella M; Basset-Seguin N; Bagot M; Pages C; Vercellino L; Maisonobe T; Lebbé C
Melanoma Res; 2017 Oct; 27(5):511-515. PubMed ID: 28692456
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effects of antibiotic drug mefloquine against cervical cancer through impairing mitochondrial function and inhibiting mTOR pathway.
Li H; Jiao S; Li X; Banu H; Hamal S; Wang X
Can J Physiol Pharmacol; 2017 Jan; 95(1):43-50. PubMed ID: 27831748
[TBL] [Abstract][Full Text] [Related]
39. Vitamin C sensitizes BRAF
Su X; Li P; Han B; Jia H; Liang Q; Wang H; Gu M; Cai J; Li S; Zhou Y; Yi X; Wei W
J Exp Clin Cancer Res; 2021 Jan; 40(1):34. PubMed ID: 33468157
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
